-Reuters
Catalyst Pharmaceuticals Completes The Acquisition Of U.S. Rights To FYCOMPA (Perampanel) CIII
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy
Bolsters Presence in Neuroscience
Expected to be Accretive in 2023